The CAR-HEMATOTOX Risk-Stratifies Patients for Severe Infections and Disease Progression after CD19 CAR-T in R/R LBCL

In this multicenter retrospective analysis, researchers characterized early infection events and clinical outcomes in 248 patients receiving standard-of-care CD19 CAR-T for relapsed/refractory large B cell lymphoma.